Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00265200 | Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer | Phase 2 | terminated | Dec 14, 2005 | University of Louisville | funding discontinued by sponsor | Funding |
| NCT00268151 | Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in… | Phase 1 | terminated | Dec 22, 2005 | University of Louisville | Study was terminated due to lack of funding. | Funding |
| NCT01300299 | STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)(STEREO) | N/A | withdrawn | Feb 21, 2011 | University of Louisville | Unable to enroll | Enrollment / accrual |
| NCT01426620 | Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer(BIT-2) | Phase 2 | terminated | Aug 31, 2011 | University of Louisville | slow accrual | Enrollment / accrual |
| NCT02491775 | Afatinib Genomic Landscape | — | terminated | Jul 8, 2015 | Washington University School of Medicine | Changes in treatment plan affecting drug therapy choices | Other (stated, no rule matched) |
| NCT02554591 | Genomic Landscape of Ceritinib | — | terminated | Sep 18, 2015 | Washington University School of Medicine | Changes in treatment plans affecting drug therapy choices | Other (stated, no rule matched) |
| NCT02590003 | Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small… | Phase 2 | terminated | Oct 28, 2015 | Yale University | Trial was stopped after non-response to treatment. | Other (stated, no rule matched) |
| NCT02342353 | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung… | Phase 1 | terminated | Jan 19, 2015 | Washington University School of Medicine | Drug shortage | Other (stated, no rule matched) |
| NCT01090830 | Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for…(HCH003) | Phase 1 / Phase 2 | terminated | Mar 23, 2010 | Holy Cross Hospital, Florida | Principal Investigator has left institution. IND withdrawn. | Investigator |
| NCT02119650 | Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer | Phase 2 | terminated | Apr 22, 2014 | Incyte Corporation | The study was terminated as other related studies of ruxolitinib did not provide sufficient… | Efficacy / futility |
| NCT03053297 | Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell…(PANORAMA) | — | terminated | Feb 15, 2017 | AstraZeneca | Cancelled due to changes in the scientific landscape. Decision was made after thorough evaluation… | Other (stated, no rule matched) |
| NCT02393209 | Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Millennium Pharmaceuticals, Inc. | Lack of efficacy in combination. | Efficacy / futility |
| NCT00681512 | The Effect of Berries on Lung Cancer Tumors | N/A | terminated | May 21, 2008 | University of Louisville | slow accrual | Enrollment / accrual |
| NCT00003497 | Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT02134015 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or…(HER3-Lung) | Phase 3 | terminated | May 8, 2014 | Daiichi Sankyo | Pre-defined criteria for continuation were not reached | Other (stated, no rule matched) |
| NCT02326285 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in…(NeoIntercal) | Phase 2 / Phase 3 | terminated | Dec 29, 2014 | AIO-Studien-gGmbH | Due to low patient enrollment was stopped. Only one patient could be enrolled. 37 patients were… | Enrollment / accrual |
| NCT01237678 | A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell… | Phase 1 / Phase 2 | terminated | Nov 9, 2010 | ImmunoGen, Inc. | Study was stopped early due to lack of efficacy signal and safety concerns | Safety / toxicity |
| NCT01574222 | A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer(VTNSCLC) | Phase 1 | terminated | Apr 10, 2012 | VA Office of Research and Development | Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome… | Other (stated, no rule matched) |
| NCT02018523 | Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer | Phase 1 | terminated | Dec 23, 2013 | Jun Zhang | Study did not enroll enough subjects to make a statistically sound conclusion. | Enrollment / accrual |
| NCT02919462 | Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and…(HighTySy) | Phase 2 | terminated | Sep 29, 2016 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | low recruitement rate | Enrollment / accrual |
| NCT01261299 | Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer | Early Phase 1 | terminated | Dec 16, 2010 | University of California, Davis | Contract ended | Other (stated, no rule matched) |
| NCT01419587 | Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG) | N/A | terminated | Aug 18, 2011 | University of Iowa | Poor accrual and compliance | Enrollment / accrual |
| NCT00369070 | A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | Phase 2 | terminated | Aug 29, 2006 | Amgen | not stated | Not stated |
| NCT01797471 | Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III… | N/A | terminated | Feb 22, 2013 | University of Miami | not stated | Not stated |
| NCT02336061 | Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With…(IMPULSO) | — | terminated | Jan 12, 2015 | Asociación para la Investigación del Cáncer de Pulmón en Mujeres | Sponsor decision due to the low recruitment rate | Enrollment / accrual |
| NCT00794547 | Phase I/II Calcitriol in Lung Cancer | Phase 1 / Phase 2 | terminated | Nov 20, 2008 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT01511081 | Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) | Phase 2 | terminated | Jan 18, 2012 | M.D. Anderson Cancer Center | Low Accrual | Enrollment / accrual |
| NCT03130764 | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | Phase 2 | withdrawn | Apr 26, 2017 | Columbia University | PI Transferred | Other (stated, no rule matched) |
| NCT01342770 | Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung… | Phase 2 | terminated | Apr 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02947113 | Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC(HYPOLAN) | Phase 2 | withdrawn | Oct 27, 2016 | The Netherlands Cancer Institute | New studies available with immunotherapy so recruitment is no longer acceptable. | Enrollment / accrual |
| NCT01746810 | IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large… | Phase 1 | terminated | Dec 11, 2012 | New Mexico Cancer Research Alliance | Closed study as requested by PI due to lack of accruals | Enrollment / accrual |
| NCT02297087 | Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for… | N/A | terminated | Nov 21, 2014 | Western Regional Medical Center | PI no longer at site and he does | Other (stated, no rule matched) |
| NCT02405910 | Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | Phase 2 | withdrawn | Apr 1, 2015 | West Virginia University | PI Left Institution | Investigator |
| NCT00932152 | Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With… | Phase 2 | terminated | Jul 3, 2009 | University of Pittsburgh | Poor enrollment/suspended to accrual; will close per AstraZeneca request | Enrollment / accrual |
| NCT00003496 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell… | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT01065818 | Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET | N/A | terminated | Feb 9, 2010 | Columbia University | Lack of funding | Funding |
| NCT02695290 | Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status… | Phase 4 | terminated | Mar 1, 2016 | Boehringer Ingelheim | not stated | Not stated |
| NCT00881712 | Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)(LU02) | N/A | terminated | Apr 15, 2009 | University of Florida | projected enrollment rate not feasible | Enrollment / accrual |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV…(THEN) | Phase 2 | withdrawn | Aug 23, 2016 | Fondation Hôpital Saint-Joseph | medical decision | Other (stated, no rule matched) |
| NCT02121899 | Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage…(ONC006) | — | terminated | Apr 24, 2014 | Myriad Genetic Laboratories, Inc. | company decision to terminate | Sponsor / business decision |
| NCT02121925 | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in…(ONC003) | — | terminated | Apr 24, 2014 | Myriad Genetic Laboratories, Inc. | Company decision to terminate | Sponsor / business decision |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Phase 1 | terminated | Sep 2, 2015 | Merrimack Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2016 | Symphogen A/S | Symphogen made a business decision to no longer perform the clinical study | Sponsor / business decision |
| NCT02950792 | MRI Adaptive Replanning Using ViewRay | N/A | withdrawn | Nov 1, 2016 | University of Miami | Investigator Decision | Investigator |
| NCT02049151 | Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer(START2) | Phase 3 | terminated | Jan 30, 2014 | EMD Serono | The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide… | Sponsor / business decision |
| NCT01398124 | Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell… | N/A | withdrawn | Jul 20, 2011 | Milton S. Hershey Medical Center | We will not be pursuing this study. | Other (stated, no rule matched) |
| NCT02835599 | Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now(REVOLUTION) | — | terminated | Jul 18, 2016 | AstraZeneca | The study sponsor requested the study be terminated as the existing study design did not meet their… | Other (stated, no rule matched) |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | — | terminated | Mar 22, 2016 | Pathway Genomics | Patient accrual was slow due to exclusion of patients with prior cancers | Enrollment / accrual |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | Phase 2 | withdrawn | Apr 23, 2015 | John Villano | slow accrual | Enrollment / accrual |
| NCT02639234 | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Dec 24, 2015 | Gradalis, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 5, 2018source: clinicaltrials